Pharmacology of RWJ 29009, A New Potassium Channel Activator

Damiano, Bruce P.; Salata, Joseph J.; Katz, Lawrence B.; Gill, Alan; Lee, David; Sanfilippo, Pauline J.; Press, Jeffrey B.; Falotico, Robert

doi:10.1111/j.1527-3466.1994.tb00281.x

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(3)]. Despite its antihypertensive activity, RWJ 29009 (8) was claimed to be selective for coronary vasculature at low doses and has been investigated for the treatment of vasospastic angina [62]. The nitro derivatives, related to RWJ 29009 (8), have not been reported in either the thieno[3,4-b]-or in - [2,3-b]pyrans, due to difficulties in their preparation [61].…”

Section: Thienopyransmentioning

confidence: 98%

From Cromakalim to Different Structural Classes of KATP Channel Openers

Cecchetti¹,

Tabarrini²,

Sabatini³

2006

CTMC

View full text Add to dashboard Cite

ATP-Sensitive potassium channel openers (K(ATP)COs) are a group of compounds with a broad spectrum of potential therapeutic applications, as they constitute efficient tools for dampening cell excitability. Interest in the K(ATP)COs was triggered in the early 1980s by the discovery of the benzopyran-based structure cromakalim (CRK), which is a powerful smooth muscle relaxant. CRK can be considered the archetype of K(ATP)COs and is by far the most mimicked structure. In many structure-activity studies various substitutions have been made at the different positions of the benzopyran ring permitting the optimal activity to be correlated with a specific set of structural characteristics and stereochemical features of the molecule. Thus, many potent benzopyran derivatives have been identified. The benzopyran nucleus itself has also been modified in both the aromatic ring and in the pyran moiety. The intention of this review is to bring together all the different structural classes of K(ATP)COs arising from the replacement of CRK benzopyran-based structure with various ring systems; design, structure-activity relationship, and synthesis will be given.

show abstract

Section: Thienopyransmentioning

confidence: 98%